Navigation Links
Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
Date:11/2/2012

PRINCETON, N.J., Nov. 2, 2012 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately held specialty pharmaceuticals company, today announced an invitation to attend the presentation of data from its Phase 3 clinical studies.  The presentation will be held on November 5, 2012 at 7:30 a.m. pst in the Bernards Room at the Millennium Biltmore Hotel, 506 South Grand Avenue, Los Angeles. Participants are also invited to attend the presentation via a live webcast available through the "What's New" section at www.Omthera.com.  The webcast will be available for replay following the presentation.

The Phase 3 EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) trial was a 12 week, multi-center, randomized, double-blind, study of 399 patients, evaluating the efficacy and safety of three doses of Epanova in patients with fasting triglyceride levels of at least 500 mg/dL but less than 2000 mg/dL.  Patients were randomized into four dosing groups: Epanova 2g/day; Epanova 3g/day; Epanova 4g/day; and control (olive oil 4 g/day).  The primary endpoint of the trial was the percentage change in triglyceride level from baseline to week 12 and the secondary endpoint was the reduction in Non-HDL-C.

The Phase 3 ESPRIT (Epanova combined with a Statin in Patients with HypertRiglycerIdemia to Reduce Non-HDL CholesTerol) trial was a six-week, randomized, double-blind, parallel group study of 647 patients to assess the efficacy and safety of add-on Epanova to statin therapy in patients with persistent hypertriglyceridemia and high risk for cardiovascular disease. Patients were randomized into three dosing groups; Epanova 2g/day; Epanova 4g/day; and control (olive oil 4 g/day).  The primary objective of the study was to evaluate the efficacy of adding Epanova (2g or 4g daily) to statin monotherapy for lowering Non-HDL-C. Secondary objectives are to evaluate the safety of the Epanova and statin combination thera
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, Inc. ... in bioactive lipid-targeted therapeutics, received official notification from the ... granted another key patent supporting its iSONEP™ and ... patent, European patent No. 2087002, claims compositions of ... Lpath,s two lead compounds, iSONEP and ASONEP. Sonepcizumab ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Fla., Nov. 8, 2011 VR Laboratories LLC ... as chief scientific advisor.  Rothman will head scientific ... manufacture and bring to market world-class botanical consumer, ... foreign and domestic markets. In addition to assisting ...
... SPRING, Md., Nov. 8, 2011 The U.S. Food and Drug ... and caregivers on the safe disposal of needles and other ... while traveling. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... created by improperly disposing of used sharps and how users ...
Cached Medicine Technology:James Rothman Named Chief Scientific Advisor at VR Laboratories 2James Rothman Named Chief Scientific Advisor at VR Laboratories 3James Rothman Named Chief Scientific Advisor at VR Laboratories 4FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 2FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 3FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 4
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers . , “Fun, cool, and ... Citrus theme” Says Christina Austin, CEO of Pixel Film Studios. ... , Citrus comes with all the tools needed for a ... transitions for added style, a title screen for an introduction, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... ... ... ... ...
... has identified four aspects of immune system disturbance which ... different inherited risk factors which predispose to the disease ... the way towards improved diagnostics and treatments for the ... population, and lead to insights into related conditions such ...
... PCI Data Compliance ... ... card processing company for small to medium sized businesses. Recently, North American Bancard has ... provide the small to medium sized businesses of the area to take advantage of face-to-face ...
... Allergens not linked to wheezing in kids, study finds , ... early in life doesn,t affect a child,s risk of developing ... that infants were exposed to high levels of endotoxin and ... were anxious to find out, through a birth cohort study, ...
... exposure during pregnancy might increase chances of condition , ... mothers were exposed to a common but controversial chemical ... A (BPA) is a chemical commonly found in polycarbonate ... beverage cans. Production of the chemical started about 40 ...
... ... ... ... ...
Cached Medicine News:Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 2Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 3Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 4Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 5Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 6Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 7Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 8Health News:Pinpointing immune system disturbances in celiac disease 2Health News:North American Bancard in the Tri-Cities Area of East Tennessee 2Health News:Household Dirt Won't Raise Asthma Risk in Infants 2Health News:BPA May Raise Risk of Asthma in Kids 2Health News:BPA May Raise Risk of Asthma in Kids 3Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 2Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 3Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: